UnitedHealth Faces Multifaceted Regulatory Scrutiny Ahead of Earnings

The regulatory landscape for UnitedHealth Group is intensifying on multiple fronts simultaneously. As the healthcare giant approaches its quarterly earnings release, it is navigating a complex web of investigations and new legislation that could reshape its operational environment.

Quarterly Results Loom Amidst Challenges

UnitedHealth is scheduled to report its first-quarter 2026 financial results before the market opens on April 21. Market consensus anticipates earnings per share of $6.76 on revenue of approximately $109.8 billion. This follows a performance in the fourth quarter of 2025 where the company slightly exceeded expectations, posting $2.11 per share against an estimate of $2.09.

Despite the mounting regulatory pressures, the average analyst rating for the stock remains “Moderate Buy,” with a consensus price target of $372.13. This target sits significantly above the current trading level. The equity has lost roughly half its value over the past twelve months, trading well below its 52-week high of 530.30 Euro. The upcoming earnings will be closely watched for signs of a catalyst that could restore confidence among institutional investors, several of whom notably reduced their holdings in Q4 2025. On a positive note, the company’s dividend remains a stable feature, currently at $2.21 per quarter and marking 15 consecutive years of increases.

FTC Settlement Reshapes Industry Compensation

In a significant industry development, the U.S. Federal Trade Commission (FTC) reached a settlement with CVS Caremark on March 24 concerning an insulin pricing case originally filed in September 2024. UnitedHealth’s pharmacy benefit manager, OptumRx, is also named as a defendant in this litigation. This agreement mirrors a prior settlement with Cigna’s Express Scripts and aims to fundamentally alter the traditional rebate model in pharmacy benefit management. The shift is toward more transparent, fee-based compensation structures.

Should investors sell immediately? Or is it worth buying Unitedhealth?

Analysts suggest the immediate financial impact on results is likely minimal. However, the long-term view is that such settlements are designed to mitigate regulatory risk, representing a tacit acknowledgment that the previous industry compensation model is no longer politically sustainable.

State-Level Legislation Adds Another Layer

Adding to the federal scrutiny, state governments are enacting their own regulations. Washington State Governor Bob Ferguson is set to sign a new 340B pharmacy law, making it the 22nd U.S. state to regulate access to 340B contract pharmacies. Washington’s legislation is pioneering, as it is the first to combine such regulation with mandatory reporting requirements for both healthcare providers and pharmaceutical manufacturers. For integrated health conglomerates like UnitedHealth, this represents an additional operational and compliance layer to manage.

Broader Antitrust Investigation Continues

Compounding these specific issues is an ongoing antitrust investigation by the Department of Justice (DOJ) targeting UnitedHealth’s Optum unit. This probe examines potential anti-competitive practices, creating a backdrop of sustained regulatory uncertainty for the corporation’s significant growth engine.

The convergence of these federal and state actions presents a notably more complicated operating climate for UnitedHealth as it prepares to report to investors.